Status:
UNKNOWN
A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients
Lead Sponsor:
Shanghai Miracogen Inc.
Conditions:
Breast Cancer With Liver Metastases
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2 positive breast cancer with liver metastases.
Eligibility Criteria
Inclusion
- Willing to sign the informed consent form and follow the requirements specified in the protocol.
- Aged 18 to 75 (including 18 and 75), both genders; Life expectancy ≥ 12 weeks;
- The score of ECOG for performance status is 0 or 1
- Patients with HER2-positive breast cancer confirmed by central laboratory and with evidence of liver metastasis by imaging;
- Archival or biopsy tumor specimens should be provided (primary or metastatic) for HER2 testing;
- Patients must have measurable lesions according to the Response Criteria in Solid Tumors (RECISTv1.1);
- Organ functions must meet the basic requirements.
- Patients of childbearing potential are willing to take effective contraceptive measures from the time of signing the informed consent form to 6 months after last administration of the study drug.
Exclusion
- Previous history of other primary malignancies;
- Presence of peripheral neuropathy ≥ grade 2 (according to CTCAE V5.0);
- Previously received antibody-drug conjugates, investigational drugs, anti-tumor vaccines or drugs, endocrine therapy for breast cancer, radiotherapy, CYP3A4 inhibitors or inducers, anthracyclines and other treatments;
- Central nervous system metastasis and/or neoplastic meningitis;
- History of decompensated cirrhosis, or liver metastases with a single lesion ≥ 10 cm in longest diameter;
- Pleural or peritoneal effusion with combined clinical symptoms, which seriously endangers the life safety of subjects or urgently requires clinical treatment; Or pericardial effusion with combined clinical symptoms;
- Any serious or uncontrolled systemic disease judged by the investigator;
- Uncontrolled cardiac disease;
- Evidence of active infection;
- Pulmonary embolism or deep venous thrombosis within 3 months prior to study treatment;
- History of interstitial pneumonia, severe chronic obstructive pulmonary disease, severe pulmonary dysfuction, symptomatic bronchospasm, etc.;
- Patients with active autoimmune disease or a history of autoimmune diseases who are receiving immunosuppressive agents or systemic hormone therapy, and are still using them within 2 weeks prior to enrollment;
- History of hypersensitivity to any component of MRG002 or known history of hypersensitivity of ≥ Grade 3 to trastuzumab injection;
- Uncontrolled tumor-related bone pain or urgent spinal cord compression;
- Other conditions inappropriate for participation in this study, as deemed by the investigator.
Key Trial Info
Start Date :
March 23 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2023
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT05263869
Start Date
March 23 2022
End Date
October 1 2023
Last Update
December 2 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, China, 100071
2
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, China, 510300